Introduction {#sec1_1}
============

Young-onset (\< 65 years) dementia (YOD) is a challenging clinical problem with potentially devastating medical and social consequences. The differential diagnosis is wide. According to Sampson et al. in London \[[@B1]\], YOD comprises Alzheimer\'s disease in 30%, vascular dementia in 15%, frontotemporal lobar dementia in 13%, alcohol-related dementia in 12%, and dementia with Lewy bodies (DLB) in 4% of patients, with these frequencies being almost constant worldwide \[[@B2], [@B3], [@B4]\]. Arriving at the correct diagnosis is not always easy, particularly for DLB. This is because DLB is not reflected on conventional magnetic resonance imaging (MRI). We herein report the case of a man who presented with YOD (starting at age 59) without motor signs throughout the course of disease, simulating Alzheimer\'s disease. He lacked hippocampal atrophy. However, his autonomic/sleep signs and other neuroimaging findings helped diagnose him as having YOD-DLB in situ.

Case Report {#sec1_2}
===========

A 61-year-old man, the manager of a facilities division in the city government, was referred to our memory clinic by a local general physician because of his 2-year history of mild memory disorder starting at age 59. He had become unable to deliver presentations at the city council without difficulty and made small mistakes in calculations. He underwent memory tests and showed mild cognitive impairment (MCI) with executive disorder predominance, i.e., 22/30 on the Mini-Mental State Examination (MMSE; 0--30 scale, normal \> 24), 11/70 on the Alzheimer\'s Disease Assessment Scale-Cognitive Behavior Section (ADAS-cog; 0--70 scale, normal \< 10), 11/18 on the Frontal Assessment Battery (FAB; 0--18 scale, normal \> 16), and general \< 50, verbal 51, and visual \< 50 on the Wechsler Memory Scale Revised (WMS-R). A detailed history taken from him and his spouse revealed that he had started to have erectile dysfunction and anosmia (he later tested positive on an intravenous anosmia test) at age 58, followed by the MCI described above, which dominated throughout the course of disease with some fluctuations in symptoms. He had no history of hallucinations. These symptoms were followed by hypersexuality toward his spouse, constipation (infrequent bowel movements \[2 times per week, normal \> 3\] and defecation difficulty \[colonic transit time 24 h under laxative \[normal \< 39 h\]), and reported REM sleep behavior disorder (at age 60) and emotional lability (at age 61). He did not show motor signs (Hoehn-Yahr grade 0; no resting tremor, rigidity, akinesia, or postural instability), postural hypotension, sleep apnea (apnea-hypopnea index 9.4 \[normal \< 10\]), or bladder dysfunction (no detrusor overactivity or post-void residual by urodynamics). His brain MRI scan showed no hippocampal atrophy, and the z-value of the parahippocampus by a voxel-based specific regional analysis system for Alzheimer\'s disease ver. 2 (VSRAD2) was normal (0.66, normal \< 2.0). Indeed, the complete lack of motor signs had initially suggested young-onset Alzheimer\'s disease.

However, he was diagnosed with YOD-DLB \[[@B5]\] based on the neurological symptoms/signs and positive brain perfusion SPECT with voxel-based analysis (occipital hypoperfusion), nigrosome MRI (parallel dopaminergic depletion \[[@B6]\]), ioflupane (N-ω-89 fluoropropyl-2β-carbomethoxy-3β-\[4-iodophenyl\] nortropane, i.e., FP-CIT) dopamine transporter (DAT) scan (low specific binding ratio in the striatum on the right side \[--0.16\] and the left side \[--0.79, normal \> 3.0\], indicating dopaminergic depletion, with 85--90% sensitivity and specificity \[[@B7]\]) and ^123^I-metaiodo-benzylguanidine (MIBG) myocardial scintigraphy (low heart-to-mediastinum ratio on delayed imaging \[1.24, normal \> 2.0\], indicating noradrenergic depletion, with approx. 90% sensitivity and specificity \[[@B8], [@B9]\]) (Fig. [1](#F1){ref-type="fig"}). He did not have cardiac disease (cardiomyopathy, cardiac ischemia, etc.), and he was not being treated with drugs that might affect DAT scan or MIBG test.

He was started on oral memantine 20 mg/day, which ameliorated his emotional lability and facilitated concentration at work. However, his cognitive/mental status gradually deteriorated. Three years later, at age 64, he quit his work. At age 67, his MMSE scored zero (Table [1](#T1){ref-type="table"}), he could not communicate at all, had apathy/loss of initiative, and became totally dependent on his spouse for daily living, using disposable briefs for incontinence. However, his motor function was preserved (Hoehn-Yahr grading 0; no resting tremor, rigidity, or postural instability; able to walk without cane; but with mild mask-like face), apart from apraxia when sitting on a chair. At this stage, his brain MRI scan showed only mild hippocampal atrophy on the left side. He was transferred to an institution for care.

Discussion {#sec1_3}
==========

Our patient started with anosmia and erectile dysfunction (at age 58), followed by MCI of executive disorder type (at age 59). These features are in accordance with those seen in the MCI stage of DLB \[[@B10]\]. He next experienced hypersexuality, constipation, REM sleep behavior disorder (at age 60), and emotional lability (at age 61). He had no motor signs, which at first suggested young-onset Alzheimer\'s disease. However, he showed positive brain perfusion SPECT, nigrosome MRI, DAT scan, and MIBG myocardial scintigraphy. His autonomic/sleep sign, along with neuroimaging, helped to diagnose him as having YOD-DLB in situ. The obvious question arises: what explains the lack of motor signs despite the clear presence of abnormal dopaminergic imaging? We do not have an answer. However, pathology and clinical studies have shown that at least initially, DLB patients may present with cognitive/psychiatric signs alone without any motor signs \[[@B11], [@B12]\]. Our case proved that a combination of neurological vignettes (known non-cognitive, non-motor features of DLB, e.g., constipation and REM sleep behavior disorder, etc.) as well as neuroimaging can help to differentiate DLB from Alzheimer\'s disease in situ. In particular, the sensitivity and specificity of ioflupane DAT scan and MIBG myocardial scintigraphy are 85--90% \[[@B7]\] and approx. 90% \[[@B8], [@B9]\], respectively, adequate to noninvasively diagnose YOD-DLB. More recently, it has been reported that during a negative DAT scan period, a positive MIBG test result can be obtained in patients with premotor Lewy body disease \[[@B13]\]. Our case report has clear limitations, including the lack of analysis of cerebrospinal fluid for biological markers (tau, beta-amyloid, and alpha-synuclein) and no autopsy. Nevertheless, it is hoped that this case report will prompt and help facilitate a future prospective study to diagnose and follow YOD-DLB patients for their appropriate management and care.

In conclusion, we described the case of a 61-year-old man with YOD-DLB in situ. It is hoped that this case report will help facilitate a future prospective study to diagnose and follow YOD-DLB patients for appropriate management and care.
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###### 

Cognitive test of the patient

         MMSE (0--30, normal \>24)   FAB (0--18, normal \>16)   ADAS-cog (0--70, normal \<10)
  ------ --------------------------- -------------------------- -------------------------------
  2012   22                          11                         11
  2013   21                          12                         12
  2014   23                          10                         12
  2015   14                          09                         16
  2016   11                          06                         26
  2017   10                          07                         36
  2018   05--0                       na                         na

MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; ADAS-cog, Alzheimer\'s Disease Assessment Scale-Cognitive Behavior Section.
